• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD Back to Search Results
Catalog Number UNK ABSORB
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Stroke/CVA (1770); Hemorrhage/Bleeding (1888); Myocardial Infarction (1969); Perforation (2001); Renal Failure (2041); Thrombosis (2100)
Event Date 11/01/2015
Event Type  Injury  
Manufacturer Narrative
Date of event: estimated.The unique device identifier (udi) is unknown because the part and lot numbers were not provided.Date of implant: estimated.The devices were not returned for analysis as they remain implanted.A review of the lot history records and complaint histories could not be conducted because the lot and part numbers were not provided.The patient effects listed are consistent with the product risk profile and are therefore expected.A conclusive cause for the difficulties listed can not be determined based on the limited information available.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling.Article title: impact of coronary calcification on outcomes after absorb scaffold implantation: insights from the gabi-r registry.
 
Event Description
This is filed to report the serious injuries.It was reported through a research article identifying the absorb bioresorbable scaffolds that may be related to the following: cardiac death, target lesion revascularization, target vessel myocardial infarction, definite or probable scaffold thrombosis, major adverse cardiac events, hemorrhage, perforation, renal failure, stroke and percutaneous coronary intervention.This article summarizes clinical outcomes of 3140 patients with 3790 lesions, treated with the absorb bioresorbable vascular scaffold.Details are listed in the article titled, "impact of coronary calcification on outcomes after absorb scaffold implantation: insights from the gabi-r registry".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM
Type of Device
BIORESORBABLE SCAFFOLD
Manufacturer (Section D)
ABBOTT VASCULAR
26531 ynez rd.
temecula CA 92591 4628
Manufacturer (Section G)
ABBOTT VASCULAR, REG # 2024168
26531 ynez road
temecula CA 92591 4628
Manufacturer Contact
lindsey bell
26531 ynez rd.
temecula, CA 92591-4628
9519143996
MDR Report Key10805161
MDR Text Key215287398
Report Number2024168-2020-09314
Device Sequence Number1
Product Code PNY
Combination Product (y/n)Y
Reporter Country CodeGM
PMA/PMN Number
P150023
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Physician
Type of Report Initial
Report Date 11/06/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/06/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNK ABSORB
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/21/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention; Disability;
Patient Age61 YR
-
-